By Mill Chart
Last update: Feb 12, 2024
Our stock screener has singled out AMGEN INC (NASDAQ:AMGN) as a promising choice for dividend investors. NASDAQ:AMGN not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.
An integral part of ChartMill's stock analysis is the Dividend Rating, which spans from 0 to 10. This rating evaluates diverse dividend factors, including yield, historical data, growth, and sustainability. NASDAQ:AMGN has received a 7 out of 10:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:AMGN was assigned a score of 5 for health:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:AMGN was assigned a score of 7 for profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Check the latest full fundamental report of AMGN for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
AMGEN INC
NASDAQ:AMGN (4/26/2024, 7:00:00 PM)
After market: 270.3 +0.32 (+0.12%)269.98
+0.6 (+0.22%)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...
These two pharma stocks have followed distinct paths of late. Which is the better investment?
This Vanguard growth fund is home to some of the world's most innovative companies.
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.